Porownywarka
Follistatin vs Desmopressin side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | Follistatin | Desmopressin |
|---|---|---|
| Kategoria | Hormonalne | Hormonalne |
| Znany tez jako | FST | DDAVP, Stimate, Minirin |
| Zatwierdzony przez FDA | Nie | Tak |
| Status kliniczny | Investigational - Gene therapy trials Nie dotyczy | FDA Approved - Multiple indications
|
| Czego oczekiwac | Muscle growth, myostatin inhibition, body composition | Bedwetting, diabetes insipidus, bleeding disorders |
| Jak dziala | Follistatin is presented as a protein that interacts with myostatin/GDF-8 and related activin-family signals. The source describes this binding as preventing those ligands from engaging activin type II receptors, which may reduce signaling pathways that normally limit skeletal-muscle growth. Because it can affect more than one TGF-beta family ligand, its biological effects may be broader than a myostatin-only blocker. | Desmopressin is described as a V2-selective vasopressin receptor agonist. In renal collecting ducts, V2 activation raises intracellular signaling that moves aquaporin water channels into place, allowing more water to be reabsorbed and producing smaller volumes of more concentrated urine. The source also notes that desmopressin has much less V1-mediated blood-vessel constriction than vasopressin. In endothelial tissue, V2 activity can increase release of stored von Willebrand factor and factor VIII, linking the same receptor system to hemostatic effects in selected bleeding disorders. |
| Typowe dawkowanie | Limited community data available · See research protocols | Limited community data available · See research protocols |
| Dawkowanie z badań | 100-300 mcg daily · Daily · Variable protocols · Subcutaneous injection | 10-40 mcg intranasal · Varies by condition · Intranasal, oral, IV, or subcutaneous |
| Typowy czas trwania | Variable protocols | Varies by condition |
| Podanie | Subcutaneous injection | Intranasal, oral, IV, or subcutaneous |
| Timing | Morning With or without food | Morning or as directed With or without food |
| Poziom dowodów | Badania kliniczne | Zatwierdzone przez FDA |
| Mozliwe skutki uboczne |
+3 więcej
|
+3 więcej
|
| Podsumowanie researchu | The source highlights early human work with AAV1.CMV.FS344 gene transfer delivered into quadriceps muscle in six men with Becker muscular dystrophy. It reports functional improvement on the 6-minute walk test in several participants, mixed individual responses, biopsy findings consistent with less fibrosis and larger or more normalized fibers, and no serious adverse effects in that small study. The same general gene-transfer strategy is also described as having been studied in sporadic inclusion body myositis. Important limitations remain: the cited human evidence is small, open label, locally delivered, and not yet supported by large placebo-controlled trials. The source distinguishes this research from non-study use of injectable follistatin peptide for physique goals, where controlled human evidence is described as essentially absent. | The source characterizes desmopressin as a long-used approved medicine rather than an experimental peptide. It reports clinical relevance in central diabetes insipidus, nocturnal enuresis, and nocturia through reduced urine production. It also describes hemostatic use because desmopressin can raise von Willebrand factor and factor VIII, with relevance to von Willebrand disease, mild hemophilia A, and some procedure-related contexts. The main safety issue emphasized is dilutional hyponatremia from retained water, with higher concern in young children and older adults according to the supplied source. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.